- Home
- VIR
as 07-26-2024 4:00pm EST
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Upcoming Earnings Alert:
Get ready for potential market movements as Vir Biotechnology Inc. VIR prepares to release earnings report on 01 Aug 2024.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.4B | IPO Year: | 2019 |
| Target Price: | $34.14 | AVG Volume (30 days): | 902.5K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.61 - $14.27 | Next Earning Date: | 08-01-2024 |
| Revenue: | $79,599,000 | Revenue Growth: | -82.16% |
| Revenue Growth (this year): | -5.7% | Revenue Growth (next year): | -52.12% |
Stock Insider Trading Activity of Vir Biotechnology Inc. (VIR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ramasastry Saira | VIR | Director | Jun 11 '24 | Sell | $10.95 | 4,000 | $43,789.20 | 14,619 | SEC Form 4 |
| De Backer Marianne | VIR | Chief Executive Officer | Apr 3 '24 | Sell | $9.46 | 72,995 | $690,364.81 | 678,457 | SEC Form 4 |
| HANLY ANN M. | VIR | EVP & Chief Technology Officer | Apr 1 '24 | Sell | $10.05 | 2,711 | $27,250.97 | 132,069 | SEC Form 4 |
| Lee Sung | VIR | EVP & Chief Financial Officer | Mar 27 '24 | Sell | $9.89 | 6,008 | $59,404.10 | 100,492 | SEC Form 4 |
| SCANGOS GEORGE A | VIR | Director | Feb 22 '24 | Sell | $11.65 | 17,722 | $206,521.55 | 112,989 | SEC Form 4 |
| HANLY ANN M. | VIR | EVP & Chief Technology Officer | Feb 22 '24 | Sell | $10.05 | 12,296 | $123,520.70 | 134,780 | SEC Form 4 |
| Pang Phillip | VIR | EVP & Chief Medical Officer | Feb 22 '24 | Sell | $10.05 | 14,568 | $146,344.30 | 250,111 | SEC Form 4 |
| SCANGOS GEORGE A | VIR | Director | Feb 22 '24 | Sell | $10.05 | 10,028 | $100,737.28 | 130,711 | SEC Form 4 |
| Pang Phillip | VIR | EVP & Chief Medical Officer | Feb 16 '24 | Sell | $10.24 | 3,321 | $34,005.71 | 264,679 | SEC Form 4 |
| SCANGOS GEORGE A | VIR | Director | Feb 16 '24 | Sell | $10.24 | 10,878 | $111,386.37 | 157,611 | SEC Form 4 |
| SCANGOS GEORGE A | VIR | Director | Feb 16 '24 | Sell | $10.22 | 16,872 | $172,384.60 | 140,739 | SEC Form 4 |
Latest Vir Biotechnology Inc. News
VIR Breaking Stock News: Dive into VIR Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
VIR: What does Argus have to say about VIR?
Business Wire
8 days ago
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
Argus Research
10 days ago
VIR: Raising target price to $11.00
Argus Research
17 days ago
VIR: Rating increased to a HOLD
Argus Research
24 days ago
VIR: What does Argus have to say about VIR?
Business Wire
a month ago
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
Simply Wall St.
a month ago
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
Zacks
2 months ago
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
Compare VIR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VIR Vir Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.